HIV drug combo tested in 15 healthy volunteers
NCT ID NCT07002242
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial tested how the HIV drug azvudine (FNC) interacts with another HIV drug, Aluvia (lopinavir/ritonavir), in 15 healthy adults. Participants took the drugs alone and together over three 5-day cycles. The goal was to measure drug levels in the blood and check for side effects, to see if the combination could be used safely in future HIV treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Azvudine (FNC) and Aluvia (lopinavir/ritonavir)
- What this could lead to
- If successful, this could help doctors understand how to combine these two HIV drugs safely and effectively.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only looks at drug levels and safety, not whether the combination works against HIV or COVID-19.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin People's Hospital
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test